Literature DB >> 10841571

Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D.

G Hansen1, S Jin, D T Umetsu, M Conti.   

Abstract

Muscarinic cholinergic signaling plays an essential role in the control of the normal airway functions and in the development of pulmonary pathologies including asthma. In this paper we demonstrate that the airways of mice deficient in a cAMP-specific phosphodiesterase (PDE4D) are no longer responsive to cholinergic stimulation. Airway hyperreactivity that follows exposure to antigen was also abolished in PDE4D(-/-) mice, despite an apparently normal lung inflammatory infiltration. The loss of cholinergic responsiveness was specific to the airway, not observed in the heart, and was associated with a loss of signaling through muscarinic receptors with an inability to decrease cAMP accumulation. These findings demonstrate that the PDE4D gene plays an essential role in cAMP homeostasis and cholinergic stimulation of the airway, and in the development of hyperreactivity. In view of the therapeutic potentials of PDE4 inhibitors, our findings provide the rationale for novel strategies that target a single PDE isoenzyme.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841571      PMCID: PMC18727          DOI: 10.1073/pnas.97.12.6751

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  Recent progress in understanding the hormonal regulation of phosphodiesterases.

Authors:  M Conti; G Nemoz; C Sette; E Vicini
Journal:  Endocr Rev       Date:  1995-06       Impact factor: 19.871

Review 2.  Selective muscarinic receptor agonists and antagonists.

Authors:  R M Eglen; N Watson
Journal:  Pharmacol Toxicol       Date:  1996-02

Review 3.  Molecular biology of muscarinic acetylcholine receptors.

Authors:  J Wess
Journal:  Crit Rev Neurobiol       Date:  1996

4.  Asthma genetics: waiting to exhale.

Authors:  S T Holgate
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

5.  M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro.

Authors:  P W Stengel; J Gomeza; J Wess; M L Cohen
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

Review 6.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

Authors:  J A Beavo
Journal:  Physiol Rev       Date:  1995-10       Impact factor: 37.312

7.  The inverse association between tuberculin responses and atopic disorder.

Authors:  T Shirakawa; T Enomoto; S Shimazu; J M Hopkin
Journal:  Science       Date:  1997-01-03       Impact factor: 47.728

8.  Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels.

Authors:  P R Tomlinson; J W Wilson; A G Stewart
Journal:  Biochem Pharmacol       Date:  1995-06-16       Impact factor: 5.858

Review 9.  Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis.

Authors:  J M Hanifin; S C Chan
Journal:  J Invest Dermatol       Date:  1995-07       Impact factor: 8.551

Review 10.  Cyclic nucleotides and phosphodiesterases and airway function.

Authors:  P J Barnes
Journal:  Eur Respir J       Date:  1995-03       Impact factor: 16.671

View more
  51 in total

1.  A multiplicity of muscarinic mechanisms: enough signaling pathways to take your breath away.

Authors:  N M Nathanson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 3.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 4.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 5.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 6.  Phosphodiesterase inhibitors.

Authors:  Victoria Boswell-Smith; Domenico Spina; Clive P Page
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 7.  Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma.

Authors:  Raymond B Penn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-16       Impact factor: 3.000

8.  Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.

Authors:  John R Cashman; Troy Voelker; Han-Ting Zhang; James M O'Donnell
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

9.  Myosin light chain kinase is necessary for tonic airway smooth muscle contraction.

Authors:  Wen-Cheng Zhang; Ya-Jing Peng; Gen-Sheng Zhang; Wei-Qi He; Yan-Ning Qiao; Ying-Ying Dong; Yun-Qian Gao; Chen Chen; Cheng-Hai Zhang; Wen Li; Hua-Hao Shen; Wen Ning; Kristine E Kamm; James T Stull; Xiang Gao; Min-Sheng Zhu
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

10.  Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility.

Authors:  Silvia Masciarelli; Kathleen Horner; Chengyu Liu; Sun Hee Park; Mary Hinckley; Steven Hockman; Taku Nedachi; Catherine Jin; Marco Conti; Vincent Manganiello
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.